New Zealand markets closed

Twist Bioscience Corporation (TWST)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.42+0.43 (+1.16%)
At close: 04:00PM EDT
35.55 -1.87 (-5.00%)
After hours: 06:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close36.99
Bid0.00 x 2900
Ask0.00 x 1200
Day's range35.47 - 37.89
52-week range25.88 - 139.99
Avg. volume973,440
Market cap2.105B
Beta (5Y monthly)1.19
PE ratio (TTM)N/A
EPS (TTM)-3.72
Earnings date04 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est47.17
  • Business Wire

    Twist Bioscience to Present at the 2022 UBS Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., May 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on Monday, May 23 at 9:15 a.m. Eastern Time in New York.

  • GlobeNewswire

    Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

    ●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our N

  • Simply Wall St.

    Investors one-year losses grow to 71% as the stock sheds US$149m this past week

    The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...